The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
165 reports and counting
Bambusa Therapeutics Raises $90M in Series A
Bambusa Therapeutics, a Biotech company based in San Francisco, CA, has raised $90M in Series A at a $400M valuation led by Arch Venture Partners, Foresite Capital.
Bambusa Therapeutics raises $90M Series A at $400M valuation
Bambusa Therapeutics raises $90M in Series A at $400M valuation. Bispecific antibodies for immunology...
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Seres Therapeutics raises $113M Series E at $450M valuation
Seres Therapeutics raises $113M in Series E at $450M valuation. Microbiome therapeutic platform...
Crystalys Therapeutics raises $205M Series B at $900M valuation
Crystalys Therapeutics raises $205M in Series B at $900M valuation. Developing novel therapeutics for neurodegenerative diseases...
Expedition Therapeutics raises $165M Series B at $850M valuation
Expedition Therapeutics raises $165M in Series B at $850M valuation. Developing novel therapeutics for cardiometabolic diseases...
Kailera Therapeutics raises $400M Series A at $1.5B valuation
Kailera Therapeutics raises $400M in Series A at $1.5B valuation. Developing obesity therapeutics with acquired pipeline...
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.